Drug Profile
Ivarmacitinib - Arcutis Biotherapeutics/Reistone Biopharma
Alternative Names: ARQ 252 active ingredient - Jiangsu Hengrui Medicine; Ivarmacitinib sulfate - Arcutis Biotherapeutics/Reistone Biopharma; SHR-0302; SHR0302 baseLatest Information Update: 16 Jan 2024
Price :
$50
*
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Developer Jiangsu Hengrui Medicine Co.; Reistone Biopharma
- Class 2 ring heterocyclic compounds; Amides; Amines; Anti-inflammatories; Antirheumatics; Cyclopentanes; Pyrimidines; Pyrroles; Skin disorder therapies; Small molecules; Thiadiazoles
- Mechanism of Action Janus kinase 1 inhibitors; STAT3 transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Atopic dermatitis
- Phase III Non-radiographic axial spondyloarthritis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
- Phase II/III Ankylosing spondylitis; Vitiligo
- Phase II Alopecia areata; Crohn's disease
- Phase I Graft-versus-host disease
- No development reported Liver disorders; Systemic lupus erythematosus
Most Recent Events
- 15 Jan 2024 Jiangsu Hengrui Medicine Co. plans a phase I trial for Autoimmune diseases (In Volunteers) in January 2024 (PO) (NCT06202612)
- 09 Dec 2023 Efficacy and adverse events data from a phase I trial in Graft-versus-host-disease presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 05 Dec 2023 Preregistration for Atopic dermatitis (Topical), prior to December 2023 (Jiangsu Hengrui Medicine pipeline, December 2023)